Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition that causes persistent airflow limitation and respiratory symptoms such as difficulty breathing, cough, and mucus production, predominantly resulting from smoking, air pollutants, frequent respiratory infections, or untreated asthma. Standard treatments include specific inhalers to help relax and open up the airways.
Health Outcomes
- Absence of Acute Toxicity
- Absence of Treatment-Related Side Effects
- Activation of Nrf2 Pathway
- Additional Therapeutic Benefits
- Altered Chemokine Response
- Altered Innate Immune Response
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Altered Serum IL-6 Levels
- Association with Sarcopenia
- Beneficial Clinical Effects
- Changed Walking Cadence
- Changes in Inflammatory Markers
- Co-Aggregation with Pathogens
- Confirmed Safety of Treatment
- Decreased IFN-γ Levels
- Decreased Immune Response to Influenza Vaccination
- Decreased Lower Respiratory Quotient
- Decreased Oxygen Saturation
- Decreased Oxygenated Hemoglobin Level
- Delayed Onset of Illness Episode
- Duration of Symptoms
- Efficacy of Postbiotics in Immunocompromised Patients
- Elevated Antipneumococcal IgA Levels in Bronchoalveolar Lavage Fluid
- Elevated IL-6 Levels
- Elevated Interleukin-6 Levels
- Elevated Interleukin-8 Levels
- Elevated Type I IFN Expression in Lung Lymphocytes
- Enhanced Anti-inflammatory Properties
- Enhanced Antioxidant Enzyme Activity
- Enhanced Antioxidant Response
- Enhanced Antipneumococcal IgA Levels in BAL
- Enhanced Goblet Cell Function
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Influenza Resistance
- Enhanced Interferon Gamma Production
- Enhanced Phagocytosis by Monocyte-Derived Dendritic Cells
- Enhanced Pro-Inflammatory Cytokine Response
- Enhanced Protection Against Influenza Infection
- Enhanced Pulmonary Immune Response
- Enhanced Radical Scavenging Ability
- Enhanced Resistance to Respiratory Infections
- Enhanced Resistance to Streptococcus Pneumoniae Infection
- Enhanced Respiratory Burst Activity
- Enhanced Tolerance Acquisition
- Improved 5000 m Running Time
- Improved 6-Meter Walk Performance
- Improved 6-minute Walking Distance
- Improved Aerobic Capacity
- Improved Aerobic Endurance Performance
- Improved Aerobic Power
- Improved Aerobic Stability
- Improved Airway Immune Response
- Improved Airway Mucosa Condition
- Improved Airway Secretion Clearance
- Improved Anaerobic Power
- Improved Antioxidant Capacity
- Improved Antioxidant Defense
- Improved Antioxidant Levels
- Improved Antioxidative Capacity
- Improved Antioxidative Enzyme Activities
- Improved Asthmatic Condition
- Improved Average Power
- Improved Bacterial Viability Under Stress
- Improved Chest Press Strength
- Improved Clinical Outcome
- Improved Clinical Outcomes
- Improved Clinical Success
- Improved Constant Work Rate Exercise Time
- Improved Consumer Acceptance
- Improved Cytokine Levels
- Improved Cytoprotection During Oxidative Stress
- Improved Daily Activity Participation
- Improved Deep Lung Delivery Feasibility
- Improved Disease Management
- Improved Distance Traveled
- Improved Endurance
- Improved Endurance Performance
- Improved Enjoyment of Life
- Improved Environmental Stress Tolerance
- Improved Estimated VO2max
- Improved Exercise Function
- Improved Exercise Performance
- Improved FEV1
- Improved Fatigue Index
- Improved Fatigue Threshold
- Improved Fatigue Tolerance
- Improved Five Times Sit-to-Stand Time
- Improved Forced Vital Capacity
- Improved Function Score
- Improved Functional Capacity
- Improved Functional Outcome
- Improved Gain:Feed Ratio
- Improved General Activity
- Improved Global Clinical Status
- Improved Global Evaluation of Patient Scores
- Improved Global Quality of Life
- Improved Global Symptom
- Improved Glutathione Level
- Improved Glutathione Redox Ratio
- Improved Health Condition
- Improved Health Outcomes
- Improved Health Perception
- Improved Health Status Score
- Improved Health-related Quality of Life
- Improved Histopathological Findings in Lungs
- Improved Hypoxia Resistance
- Improved Immune Mechanisms Against S. pneumoniae
- Improved Inflammation Homeostasis
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Response
- Improved Influenza Infection Control
- Improved Intermittent Exercise Performance
- Improved Isokinetic Strength
- Improved JMCIS Score
- Improved Lactate Threshold
- Improved Leukocyte Recruitment
- Improved Lifespan
- Improved Limited Distance Test Performance
- Improved Longevity
- Improved Lower Body Endurance
- Improved Lower Limb Peak Power
- Improved Lower-Body Muscular Strength
- Improved Lung Barrier Function
- Improved Lung Function
- Improved Lung Injury Outcomes
- Improved Maximal Exercise Capacity
- Improved Maximal Oxygen Capacity
- Improved Maximal Oxygen Uptake
- Improved Maximal Power
- Improved Maximal Walking Performance
- Improved Muscular Endurance
- Improved Neutrophil Function
- Improved Overall Patient Outcomes
- Improved Overall Symptom Relief
- Improved Overall Symptom Score
- Improved Overall Symptoms
- Improved Oxidative Status
- Improved Oxidative Stress Levels
- Improved Oxidative Stress Resistance
- Improved Oxidative Stress Tolerance
- Improved Oxygenation Index
- Improved Parent/Caregiver Health-Related Quality of Life
- Improved Patient Satisfaction
- Improved Peak Anaerobic Power
- Improved Phagocytic Capacity of Polymorphonuclear Cells
- Improved Phagocytic Function
- Improved Physical Domain Score
- Improved Physical Function
- Improved Physical Health-Related Quality of Life
- Improved Physical Mobility
- Improved Physical Performance
- Improved Physical Quality of Life
- Improved Physical Role Limitation
- Improved Physical Well-being
- Improved Physiological Parameters
- Improved Pneumococcal Infection Outcomes
- Improved Pulmonary Function
- Improved Quadriceps Strength
- Improved Quality of Life
- Improved Repetitions to Failure
- Improved Resistance to Pneumococcal Respiratory Infection
- Improved Resistance to Secondary Pneumococcal Pneumonia
- Improved Respiratory Humoral Response
- Improved Respiratory Immune Function
- Improved Respiratory Immunity
- Improved Respiratory Innate Immune Response
- Improved Respiratory Mucosal Barrier Function
- Improved Respiratory Tract Health
- Improved Serum Antioxidant Capacity
- Improved Serum Immunity
- Improved Standing Balance
- Improved Strength Endurance
- Improved Survival Rate Against Influenza Virus
- Improved Swimming Performance
- Improved Symptom Control
- Improved Symptom Relief
- Improved Symptom Score
- Improved Symptoms of Chronic Condition
- Improved Time to Exhaustion
- Improved Tolerance
- Improved Total Antioxidant Status
- Improved Total Antioxidative Status
- Improved VO2 Max
- Improved VO2max
- Improved Walking Distance
- Improved Walking Speed
- Improved Work Capacity
- Improved Yo-Yo Test Performance
- Incidence of Death
- Increase in Persistent Diseased Sites
- Increased Abundance of Goblet Cells
- Increased Anti-Inflammatory Cytokine IL-6 Production
- Increased Anti-Pneumococcal Antibody Levels
- Increased Anti-Viral Factor Expression in Lung
- Increased Antibacterial Compound Production
- Increased Bacillus Spore Counts
- Increased C-Reactive Protein Levels
- Increased Catalase Activity
- Increased Cytokine Production
- Increased Cytokine Response
- Increased Cytokine Secretion
- Increased Days Alive and Out of Hospital
- Increased Deoxygenated Hemoglobin Level
- Increased Digestible Energy
- Increased Endogenous Acrolein Formation
- Increased Endurance Swimming Time
- Increased Exercise Capacity
- Increased Exercise Endurance
- Increased Expression of CD206
- Increased Expression of Oxidation-Related Gene
- Increased Functional Capacity
- Increased GSH/GSSG Ratio
- Increased General Morbidity
- Increased Glutathione Peroxidase Levels
- Increased Goblet Cell Count
- Increased Goblet Cell Differentiation
- Increased Hospital Admissions
- Increased Hydrogen Peroxide Production
- Increased IFN-γ Concentration
- Increased IL-6 Levels in Early Phase
- Increased IL-8 Levels at 24 Hours
- Increased Incidence of Pulmonary Exacerbations
- Increased Infection Frequency
- Increased Inflammatory Cytokines
- Increased Interleukin 8 Levels
- Increased Interleukin-6 Production in Macrophages
- Increased Invasive Interventions Requirement
- Increased Lactate Production
- Increased Lactic Acid Levels
- Increased Late-Onset Sepsis Incidence
- Increased Length
- Increased Lung CD3+CD4+ IFN-γ+ T Cells
- Increased Malondialdehyde Levels
- Increased Maximal Incremental Cycling Capacity
- Increased Monocarboxylic Acid Transporter mRNAs
- Increased Mortality
- Increased Mortality Rate
- Increased Mortality in Patients with Enterococcal Bacteremia
- Increased Mucin Production
- Increased Mucin Secretion
- Increased Mucus Binding Capacity
- Increased Nrf2 Level
- Increased Nrf2 Protein Content
- Increased Number of Persistent Diseased Sites
- Increased Oxidative Stress
- Increased Post-Infection Lung Monocyte Levels
- Increased Pro-inflammatory Cytokine IL-6
- Increased Pro-inflammatory Cytokine Production
- Increased Pro-inflammatory Cytokine Release
- Increased Pro-inflammatory Cytokines in Early Healing Phase
- Increased Proportion of Healthy Days
- Increased Protease Levels
- Increased Reactive Oxygen Species Production
- Increased Respiratory Burst Activity
- Increased Respiratory Sensitization
- Increased Risk of Opportunistic Pathogenicity
- Increased Serum Amyloid Protein
- Increased Serum IL-10 Levels
- Increased Serum Immunoglobulin A (IgA) Levels
- Increased Serum Lysozyme Levels
- Increased Serum Macrophage Inflammatory Protein-1β Levels
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Skin Mucus Protein Levels
- Increased Superoxide Dismutase Levels
- Increased TIMP-1 Levels
- Increased TNF-α Production
- Increased Time to Exhaustion
- Increased Time to Ventilatory Threshold
- Increased Total Serum Antioxidant Capacity
- Increased Transforming Growth Factor-β Levels
- Increased Treatment Effectiveness
- Increased Tumor Necrosis Factor-Alpha Levels
- Increased Viable Cell Antioxidant Activity
- Maintained Clinical Safety Parameters
- Maintained Physical Activity Level
- Maintained Physical Performance
- Maintenance of NK Cell Activity
- Managed Cystic Fibrosis
- Mitigated Adverse Impacts of IoNPs on Physiological Processes
- Mitigated Adverse Physiological Processes
- Modulated Cytokine Production
- Modulated Inflammatory Cytokine Levels
- Modulated Inflammatory Response
- Modulated Pulmonary Innate Immune Microenvironment
- Modulated Pulmonary Innate Immune Response
- No Change in Anxiety
- No Clear Effect on Depression
- No Difference in Adverse Events
- No Meaningful Change in IL-8
- No Significant Change in Inflammatory Responses
- No Significant Change in Lean Body Mass
- No Significant Impact on Bacterial Community Composition or Diversity
- No Significant Reduction in Lower Respiratory Tract Infections
- Persistent Diseased Sites
- Preserved Anti-pseudomonal Activity
- Prevented Sepsis
- Prevention of Aberrant Inflammatory Response
- Prevention of Mucus Barrier Decline
- Prolonged Survival Time in Influenza Infection
- Reduced Adherence Attrition
- Reduced Adipose Tissue Wasting
- Reduced Airway Inflammation
- Reduced Airway Inflammation Score
- Reduced Airway Pathological Responses
- Reduced Airway Remodeling
- Reduced All-Cause Mortality
- Reduced Alpha-1-Antitrypsin Level
- Reduced BCG Phagocytic Intake
- Reduced Bacterial Infection Severity
- Reduced Bacterial Load in Lungs
- Reduced Bicarbonate Level
- Reduced Body Mass
- Reduced Cause-Specific Mortality
- Reduced Cellular Damage
- Reduced Chemokine Production
- Reduced Colonization with Multiple Organisms
- Reduced Common Cold Incidence in Susceptible Populations
- Reduced Community Healthcare Costs
- Reduced Composite Symptom Score
- Reduced Concomitant Medication Usage
- Reduced Corticosteroid Usage
- Reduced Cost-Effectiveness in Reducing AAD
- Reduced Cumulative Incidents of CIDs in Smokers
- Reduced Cumulative Morbidity Rates
- Reduced Cumulative Mortality
- Reduced Cytokine Response
- Reduced Daily Episode Severity
- Reduced Disability
- Reduced Disease Progression
- Reduced Disease Severity
- Reduced Duration of Hospitalization
- Reduced Duration of Mechanical Ventilation
- Reduced Emergency Care Unit Stay Duration
- Reduced Energy Intake
- Reduced Eosinophil Count
- Reduced Eosinophils in Bronchoalveolar Lavage Fluid
- Reduced Episode Frequency
- Reduced Exercise-Induced Biochemical Markers
- Reduced Exertional Dyspnea
- Reduced Exhaustion
- Reduced Exposure to Harmful Substances
- Reduced Expression of Inflammation-Related Genes
- Reduced Expression of Pro-Inflammatory Cytokines in Lung
- Reduced F2-Isoprostanes
- Reduced Fatigue Levels
- Reduced Fatigue Severity
- Reduced Food Intake
- Reduced Free Radical Levels
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced Functional Iron Deficiency
- Reduced GAS Adherence to Host Epithelial Cells
- Reduced Glutathione Loss
- Reduced Glutathione Redox Ratio
- Reduced Harmful Bacterial Populations
- Reduced Healthcare Costs
- Reduced Heat Stress
- Reduced Hospital Length of Stay
- Reduced Hospital Readmission Risk
- Reduced Hospital Stay
- Reduced Hospital Stay Duration
- Reduced Hospitalisation
- Reduced Hospitalization Duration
- Reduced Hospitalization Rate
- Reduced Hypoxia
- Reduced ICU Length of Stay
- Reduced IFN-γ Levels
- Reduced IL-5 Levels
- Reduced IL-6 Secretion
- Reduced IL-8 Production
- Reduced IL-8 Secretion
- Reduced Immune Cell Infiltration
- Reduced Immune Cell Proliferation
- Reduced Immunoinflammatory Markers
- Reduced Impact of Gram-negative Microorganisms
- Reduced In-hospital Mortality
- Reduced Incidence of Bacterial Pneumonia
- Reduced Incidence of Chronic Inflammatory Diseases in Smokers
- Reduced Incidence of Influenza
- Reduced Incidence of Respiratory Illness
- Reduced Infection Frequency
- Reduced Inflammation Levels
- Reduced Inflammation in the Lower Respiratory Tract
- Reduced Inflammatory Injury
- Reduced Inflammatory Markers
- Reduced Inflammatory Molecules
- Reduced Inflammatory Parameters
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Status
- Reduced Innate Immune Cell Activation
- Reduced Interference with Daily Life
- Reduced Interferon-Gamma Levels
- Reduced Interleukin-15 Levels
- Reduced Length of Hospitalization
- Reduced Length of Stay
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Lifespan
- Reduced Lifetime Prevalence of Wheeze
- Reduced Lung Damage
- Reduced Lung Histopathology Scores
- Reduced Lung Inflammation
- Reduced Lung Injury
- Reduced Lung Neutrophils
- Reduced Lung Tissue Damage
- Reduced MCP-1/CCL2 Levels
- Reduced Malonaldehyde Levels
- Reduced Mechanical Ventilation Duration
- Reduced Microbial Richness
- Reduced Morbidity
- Reduced Morbidity Rate
- Reduced Mortality
- Reduced Mortality Rate
- Reduced Mortality Rate Before Discharge
- Reduced Mortality Risk
- Reduced Mortality from COPD
- Reduced Mortality from Frailty
- Reduced Mortality from Influenza Infection
- Reduced Mucus Secretion
- Reduced Muscle Hydration
- Reduced Muscle Protein Breakdown
- Reduced Muscular Endurance
- Reduced NO Secretion Induced by LPS
- Reduced NREM Sleep Quality
- Reduced Non-Programmed Medical Visits
- Reduced Occurrence of Pasty Vent
- Reduced Opportunistic Pathogens
- Reduced Organ Failure Severity
- Reduced Overall Mortality Rate
- Reduced Overall Symptom Score
- Reduced Oxidative Damage
- Reduced Oxidative Stress
- Reduced Oxidative Tissue Injury
- Reduced Oxidized Glutathione Level
- Reduced Oxygen Cost of Exercise
- Reduced PICU Discharge Time
- Reduced Pathogen Adherence
- Reduced Pathogenic Colonies
- Reduced Peak Inspiratory Pressure
- Reduced Phospho-p65 Translocation
- Reduced Physical Activity
- Reduced Physical Fatigue
- Reduced Physical Symptoms
- Reduced Physiological Impairments
- Reduced Plasma Malondialdehyde Levels
- Reduced Pneumococcal Adherence
- Reduced Post-Exercise Lactate Levels
- Reduced Power
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-Inflammatory Fatty Acids
- Reduced Pro-inflammatory Biomarker Level
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Proinflammatory Cytokine Production
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Mediators
- Reduced Proinflammatory Profile
- Reduced Proinflammatory Signaling
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Proportion of Pathogenic Genera
- Reduced Proportion of Volunteers with At Least One CID
- Reduced Pseudomonas Levels
- Reduced Pseudomonas aeruginosa-Induced Damage
- Reduced Pulmonary Exacerbations
- Reduced Pulmonary Free-CML
- Reduced Pulmonary Inflammation
- Reduced Quadriceps Muscle Cross-Sectional Area
- Reduced Reactive Oxygen Species Formation
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Respiratory Burst Activity
- Reduced Respiratory Illness
- Reduced Respiratory Inflammation Severity
- Reduced Respiratory Rate
- Reduced Respiratory Symptom Days
- Reduced Respiratory Symptoms
- Reduced Risk of COVID-19 Progression
- Reduced Risk of Prolonged Respiratory Infections
- Reduced Risk of Upper Respiratory Tract Infections
- Reduced Serious Adverse Events
- Reduced Serum Chemokine Levels
- Reduced Serum IL-6 Levels
- Reduced Serum Inflammatory Cytokines
- Reduced Serum Inflammatory Factors
- Reduced Severity of Acute Respiratory Infection
- Reduced Severity of Influenza Infection
- Reduced Severity of Lung Injuries
- Reduced Severity of Symptoms Per Day
- Reduced Significant Weight Loss
- Reduced Staphylococcus aureus Colonization
- Reduced Steroid Usage
- Reduced Streptococcus pneumoniae in Lung
- Reduced Subjective Symptoms
- Reduced Survival Rate
- Reduced Susceptibility to Pneumococcal Infection
- Reduced Swimming Time
- Reduced Symptom Severity Scale Score
- Reduced T Cell Responsiveness
- Reduced Total Cells in Bronchoalveolar Lavage Fluid
- Reduced Total Symptom Score
- Reduced Transforming Growth Factor Beta Levels
- Reduced Treatment Costs
- Reduced Upper Respiratory Infections
- Reduced Use of Rescue Medication
- Reduced Virus Titers in Bronchoalveolar Lavage Fluid
- Reduced Walking Time
- Reduced Weight Loss
- Reduced Wheezing
- Regulated Cytokine Levels
- Regulated Inflammation
- Regulated Inflammatory Cytokines
- Regulated Inflammatory Markers
- Regulated Oxidative Stress
- Restored Goblet Cell Function
- Similar Frequency of Adverse Events
- Slower Weight Gain
- Stabilized Disease Progression
- Stable Systemic Inflammatory Response
- Supported Physiological Function in Elderly
- Unchanged Body Composition
- Unchanged Body Weight
- Unchanged IFN-γ Levels
- Unchanged Inflammatory Marker Levels
- Well-Tolerated Long-Term Use